Kosj Yamoah1,2, Francis A Asamoah3, Afua O D Abrahams4, Shivanshu Awasthi2, James E Mensah5, Jasreman Dhillon6, Brandon A Mahal7, Serigne Magueye Gueye8, Mohamed Jalloh8, Sahar J Farahani9, Priti Lal10, Timothy R Rebbeck11, Joel Yarney3. 1. Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA. 2. Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA. 3. National Center for Radiotherapy, Oncology and Nuclear Medicine, Korle Bu Teaching Hospital Accra, Accra, Ghana. 4. Department of Pathology, University of Ghana Medical School, Korle bu Teaching Hospital, Accra, Ghana. 5. Department of Surgery, University of Ghana Medical School, Korle bu Teaching Hospital, Accra, Ghana. 6. Department of Pathology, H. Lee Moffitt Cancer Center, Tampa, Florida, USA. 7. Department of Radiation Oncology, University of Miami, Miami, Florida, USA. 8. Hospital General Idrissa Pouye, Dakar, Senegal. 9. Department of Pathology, Stony Brook University, New York city, New York, USA. 10. Department of Pathology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 11. Dana Farber Cancer Institute and Harvard TH Chan School of Public Health, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Native African men (NAM) experience a disproportionate burden of prostate cancer (PCa) and have higher mortality rates compared to European American men (EAM). While socioeconomic status has been implicated as a driver of this disparity, little is known about the genomic mechanisms and distinct biological pathways that are associated with PCa of native men of African origin. METHODS: To understand biological factors that contribute to this disparity we utilized a total of 406 multi-institutional localized PCa samples, collected by Men of African Descent and Carcinoma of the Prostate biospecimen network and Moffitt Cancer Center/University of Pennsylvania Health science system. We performed comparative genomics and immunohistochemistry to identify the biomarkers that are highly enriched in NAM from west Africa and compared them with African American Men (AAM) and EAM. Quantified messenger RNA expression and Median H scores based on immune reactivity of staining cells, were compared using Mann Whitney test. For gene expression analysis, p values were further adjusted for multiple comparisons using false discovery rates. RESULTS: Immunohistochemical analysis on selected biomarkers showed a consistent association between ETS related gene (ERG) status and race with 83% of NAM exhibiting tumors that lacked TMPRSS2-ERG translocation (ERGnegative ) as compared to AAM (71%) and EAM (52%). A higher proportion of NAM (29%) were also found to be double negative (ERGnegative and PTENLoss ) as compared to AAM (6%) and EAM (7%). NAM tumors had significantly higher immunoreactivity (H-score) for PSMA, and EZH2, whereas they have lower H-score for PTEN, MYC, AR, RB and Racemase, (all p < .05). Comparative genomics revealed that NAM had significant transcriptomic variability in AR-activity score. In pathways enrichment analysis NAM tumors exhibited the enrichment of proinflammatory pathways including cytokine, interleukins, inflammatory response, and nuclear factor kappa B signaling. CONCLUSIONS: Prostate tumors in NAM are genomically distinct and are characterized by the dysregulation of several biomarkers. Furthermore, these tumors are also highly enriched for the major proinflammatory pathways. These distinct biological features may have implications for diagnosis and response to targeted therapy among Black men, globally.
BACKGROUND: Native African men (NAM) experience a disproportionate burden of prostate cancer (PCa) and have higher mortality rates compared to European American men (EAM). While socioeconomic status has been implicated as a driver of this disparity, little is known about the genomic mechanisms and distinct biological pathways that are associated with PCa of native men of African origin. METHODS: To understand biological factors that contribute to this disparity we utilized a total of 406 multi-institutional localized PCa samples, collected by Men of African Descent and Carcinoma of the Prostate biospecimen network and Moffitt Cancer Center/University of Pennsylvania Health science system. We performed comparative genomics and immunohistochemistry to identify the biomarkers that are highly enriched in NAM from west Africa and compared them with African American Men (AAM) and EAM. Quantified messenger RNA expression and Median H scores based on immune reactivity of staining cells, were compared using Mann Whitney test. For gene expression analysis, p values were further adjusted for multiple comparisons using false discovery rates. RESULTS: Immunohistochemical analysis on selected biomarkers showed a consistent association between ETS related gene (ERG) status and race with 83% of NAM exhibiting tumors that lacked TMPRSS2-ERG translocation (ERGnegative ) as compared to AAM (71%) and EAM (52%). A higher proportion of NAM (29%) were also found to be double negative (ERGnegative and PTENLoss ) as compared to AAM (6%) and EAM (7%). NAM tumors had significantly higher immunoreactivity (H-score) for PSMA, and EZH2, whereas they have lower H-score for PTEN, MYC, AR, RB and Racemase, (all p < .05). Comparative genomics revealed that NAM had significant transcriptomic variability in AR-activity score. In pathways enrichment analysis NAM tumors exhibited the enrichment of proinflammatory pathways including cytokine, interleukins, inflammatory response, and nuclear factor kappa B signaling. CONCLUSIONS: Prostate tumors in NAM are genomically distinct and are characterized by the dysregulation of several biomarkers. Furthermore, these tumors are also highly enriched for the major proinflammatory pathways. These distinct biological features may have implications for diagnosis and response to targeted therapy among Black men, globally.
Authors: Carol E DeSantis; Kimberly D Miller; Ann Goding Sauer; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2019-02-14 Impact factor: 508.702
Authors: Shuang G Zhao; Jonathan Lehrer; S Laura Chang; Rajdeep Das; Nicholas Erho; Yang Liu; Martin Sjöström; Robert B Den; Stephen J Freedland; Eric A Klein; R Jeffrey Karnes; Edward M Schaeffer; Melody Xu; Corey Speers; Paul L Nguyen; Ashley E Ross; June M Chan; Matthew R Cooperberg; Peter R Carroll; Elai Davicioni; Lawrence Fong; Daniel E Spratt; Felix Y Feng Journal: J Natl Cancer Inst Date: 2019-03-01 Impact factor: 13.506
Authors: Marco Matejcic; Yesha Patel; Jenna Lilyquist; Chunling Hu; Kun Y Lee; Rohan D Gnanaolivu; Steven N Hart; Eric C Polley; Siddhartha Yadav; Nicholas J Boddicker; Raed Samara; Lucy Xia; Xin Sheng; Alexander Lubmawa; Vicky Kiddu; Benon Masaba; Dan Namuguzi; George Mutema; Kuteesa Job; Dabanja M Henry; Sue A Ingles; Lynne Wilkens; Loic Le Marchand; Stephen Watya; Fergus J Couch; David V Conti; Christopher A Haiman Journal: JCO Precis Oncol Date: 2020-01-31
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Robert T Dess; Holly E Hartman; Brandon A Mahal; Payal D Soni; William C Jackson; Matthew R Cooperberg; Christopher L Amling; William J Aronson; Christopher J Kane; Martha K Terris; Zachary S Zumsteg; Santino Butler; Joseph R Osborne; Todd M Morgan; Rohit Mehra; Simpa S Salami; Amar U Kishan; Chenyang Wang; Edward M Schaeffer; Mack Roach; Thomas M Pisansky; William U Shipley; Stephen J Freedland; Howard M Sandler; Susan Halabi; Felix Y Feng; James J Dignam; Paul L Nguyen; Matthew J Schipper; Daniel E Spratt Journal: JAMA Oncol Date: 2019-07-01 Impact factor: 31.777
Authors: Klara Stefflova; Matthew C Dulik; Jill S Barnholtz-Sloan; Athma A Pai; Amy H Walker; Timothy R Rebbeck Journal: PLoS One Date: 2011-01-06 Impact factor: 3.240
Authors: Kimiko L Krieger; Jie H Gohlke; Kevin J Lee; Danthasinghe Waduge Badrajee Piyarathna; Patricia D Castro; Jeffrey A Jones; Michael M Ittmann; Natalie R Gassman; Arun Sreekumar Journal: Cancers (Basel) Date: 2022-02-17 Impact factor: 6.639
Authors: William G Nelson; Otis W Brawley; William B Isaacs; Elizabeth A Platz; Srinivasan Yegnasubramanian; Karen S Sfanos; Tamara L Lotan; Angelo M De Marzo Journal: J Clin Invest Date: 2022-02-01 Impact factor: 14.808